Outcome of Adult Acute Lymphoblastic Leukemia in South East of Iran (Zahedan)

Mohammad Ali Mashhadi; Mohhamad Mahdi Koushyar; Mehdi Mohammadi

International Journal of Cancer Management

The Official Journal of Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences

Outlines

Abstract
Fulltext
Copyright

Outcome of Adult Acute Lymphoblastic Leukemia in South East of Iran (Zahedan)

Author(s):

Mohammad Ali Mashhadi^1,*,

Mohhamad Mahdi Koushyar²,

Mehdi Mohammadi³

1Dept. of Hematology and Oncology, Genetic Research Center , Ali Ebne Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran

2Dept. of Hematology and Oncology, Emam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

3. Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

International Journal of Cancer Management:Vol. 5, issue 3; e80814

Published online:Sep 30, 2012

Article type:Research Article

Received:Jan 30, 2012

Accepted:Apr 07, 2012

How to Cite:Mohammad Ali MashhadiMohhamad Mahdi Koushyar Mehdi MohammadiOutcome of Adult Acute Lymphoblastic Leukemia in South East of Iran (Zahedan).Int J Cancer Manag.5(3):e80814.

Abstract

Background: Acute lymphoblastic leukemia is a lymphoid malignancy, resulting from autonomous proliferation of monoclonal abnormal stem cell. The aim of this study was to evaluate the response rate and prognostic factor of adult patients suffering from acute lymphoblastic leukemia, who were treated with chemotherapy in south east of Iran and demographic methods were used for this study.

Methods: This study was conducted in Ali Ebne Abitaleb Hospital in south east of Iran (Zahedan) from 2003-2010. All adult patients with acute lymphoblastic leukemia in hematology ward received Vincristin, Daunorubicin, Cyclophosphamide, Prednisolone and high dose Methotrexate for induction therapy. All patients' information was recorded and multivariate analysis and survival studies were performed by using Kaplan-Meier statistics.

Results: Sixty six adult patients entered. Mean age of them was 33 years old (16-68), that 53 (80.3%) cases were male and 13 cases were female. Fifty one (77.3%) cases experienced complete remission and 15 (22.7%) cases had no remission state. In the following year 53% ( 33) was alive with complete remission and 47% ( 31) were dead. Median survival was 13 months. In the end of study 30 cases were in complete remission and alive and 36 (54.5%) were dead.

Conclusion: Our results were comparable with other studies and minimally better than those studies.

Keywords

Acute lymphoblastic leukemia

Stem cell

Outcome

Fulltext

Full text is available in PDF.

comments